Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01128153




Registration number
NCT01128153
Ethics application status
Date submitted
20/05/2010
Date registered
21/05/2010
Date last updated
10/08/2012

Titles & IDs
Public title
Saxagliptin Triple Oral Therapy
Scientific title
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea
Secondary ID [1] 0 0
CV181-117
Secondary ID [2] 0 0
D1680L00006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Saxagliptin
Treatment: Drugs - Placebo

Experimental: Saxagliptin 5 mg once daily -

Placebo comparator: Placebo once daily -


Treatment: Drugs: Saxagliptin
5 mg tablet once daily for 24 weeks to be taken orally

Treatment: Drugs: Placebo
tablet once daily for 24 weeks to be taken orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)
Timepoint [1] 0 0
From Baseline to Week 24 weeks
Secondary outcome [1] 0 0
Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL]
Timepoint [1] 0 0
From Baseline to Week 24
Secondary outcome [2] 0 0
Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L]
Timepoint [2] 0 0
From Baseline to Week 24
Secondary outcome [3] 0 0
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL]
Timepoint [3] 0 0
From Baseline to Week 24
Secondary outcome [4] 0 0
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L]
Timepoint [4] 0 0
From Baseline to Week 24
Secondary outcome [5] 0 0
Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF)
Timepoint [5] 0 0
From Baseline to Week 24

Eligibility
Key inclusion criteria
* Written Informed Consent
* Males or females with type 2 diabetes with inadequate glycaemic control (HbA1c > or = 7% and < or = 10%) despite being on combination of metformin and sulfonylurea for at least 8 weeks prior to Visit 1
* BMI < or = 40 kg/m2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Symptoms of poorly controlled diabetes including but not limited to marked polyuria and marked polydipsia with > 10% weight loss in 3 months prior to entry, or other signs and symptoms
* History of diabetic ketoacidosis or hyperosmolar non-ketotic coma
* Current or prior use within 3 months of Visit 1 of insulin, DDP4 inhibitor, GLP-1 analogues, and/or other oral anti-diabetic agents (other than metformin or sulfonylurea)
* Treatment with CYP3A4 inducers and/or potent CYP3A4/5 inhibitor
* Estimated CrCl < 60 ml/min at Visit 2
* CHF (NYHA class III or IV) and/or LVEF <40%
* Active liver disease and/or significant abnormal liver function defined as AST and/or ALT > 3 x ULN and/or bilirubin > 2.0 mg/dL at Visit 2.
* Creatine kinase > or = 10 x ULN at Visit 2

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2011
Sample size
Target
Accrual to date
Final
257
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Research Site - Broadmeadow
Recruitment hospital [2] 0 0
Research Site - Wollongong
Recruitment hospital [3] 0 0
Research Site - Daw Park
Recruitment hospital [4] 0 0
Research Site - Elizabeth Vale
Recruitment hospital [5] 0 0
Research Site - Melbourne
Recruitment hospital [6] 0 0
Research Site - Camperdown
Recruitment hospital [7] 0 0
Research Site - Herston
Recruitment postcode(s) [1] 0 0
- Broadmeadow
Recruitment postcode(s) [2] 0 0
- Wollongong
Recruitment postcode(s) [3] 0 0
- Daw Park
Recruitment postcode(s) [4] 0 0
- Elizabeth Vale
Recruitment postcode(s) [5] 0 0
- Melbourne
Recruitment postcode(s) [6] 0 0
- Camperdown
Recruitment postcode(s) [7] 0 0
- Herston
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Newfoundland and Labrador
Country [2] 0 0
Canada
State/province [2] 0 0
Nova Scotia
Country [3] 0 0
Canada
State/province [3] 0 0
Ontario
Country [4] 0 0
Canada
State/province [4] 0 0
Prince Edward Island
Country [5] 0 0
India
State/province [5] 0 0
Haryana
Country [6] 0 0
India
State/province [6] 0 0
Karnataka
Country [7] 0 0
India
State/province [7] 0 0
Madhya Pradesh
Country [8] 0 0
India
State/province [8] 0 0
Maharashtra
Country [9] 0 0
India
State/province [9] 0 0
Tamil Nadu
Country [10] 0 0
Korea, Republic of
State/province [10] 0 0
Kangwon-do
Country [11] 0 0
Korea, Republic of
State/province [11] 0 0
Kyounggi-do
Country [12] 0 0
Korea, Republic of
State/province [12] 0 0
Daegu
Country [13] 0 0
Korea, Republic of
State/province [13] 0 0
Seoul
Country [14] 0 0
Thailand
State/province [14] 0 0
Bangkok
Country [15] 0 0
United Kingdom
State/province [15] 0 0
Berks
Country [16] 0 0
United Kingdom
State/province [16] 0 0
Cambridgeshire
Country [17] 0 0
United Kingdom
State/province [17] 0 0
Kent
Country [18] 0 0
United Kingdom
State/province [18] 0 0
Wiltshire
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Ashford
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Belfast
Country [21] 0 0
United Kingdom
State/province [21] 0 0
Blackpool
Country [22] 0 0
United Kingdom
State/province [22] 0 0
Chesterfield
Country [23] 0 0
United Kingdom
State/province [23] 0 0
Coventry
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Glasgow
Country [25] 0 0
United Kingdom
State/province [25] 0 0
Peterborough
Country [26] 0 0
United Kingdom
State/province [26] 0 0
Wellingborough

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jayanti Visvanthan, MD
Address 0 0
AstraZeneca
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01128153